Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
iX Biopharma Ltd. ( (SG:42C) ) has issued an update.
iX Biopharma Ltd. has successfully raised S$6.7 million through an upsized share placement, surpassing its initial target of S$5.0 million due to strong investor demand. The funds will support the company’s strategic expansion into the U.S. market, leveraging its compounding pharmacy model to commercialize novel sublingual products without additional R&D costs. This move is expected to strengthen iX Biopharma’s position in the world’s largest healthcare market and drive its next phase of growth, focusing on its compounding, wellness, and drug development divisions.
More about iX Biopharma Ltd.
iX Biopharma Ltd. operates in the healthcare industry, focusing on the development and commercialization of sublingual pharmaceutical and wellness products. The company is known for its innovative SL-NAD+ product and aims to enhance longevity and healthspan. It is expanding its market presence, particularly in the U.S., through compounding pharmacies.
Average Trading Volume: 10,616,060
Technical Sentiment Signal: Buy
Current Market Cap: S$104.9M
Find detailed analytics on 42C stock on TipRanks’ Stock Analysis page.